Rigel Pharmaceuticals
RIGL
135 hedge funds and large institutions have $265M invested in Rigel Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 52 increasing their positions, 33 reducing their positions, and 8 closing their positions.
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
58% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 33
13% more capital invested
Capital invested by funds: $234M → $265M (+$30.7M)
7% more funds holding
Funds holding: 126 → 135 (+9)
0.27% less ownership
Funds ownership: 8.87% → 8.6% (-0.27%)
10% less call options, than puts
Call options by funds: $44K | Put options by funds: $49K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.2M |
| 2 |
Renaissance Technologies
New York
|
+$2.89M |
| 3 |
TA
Tamarack Advisers
Carlsbad,
California
|
+$2.34M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$1.99M |
| 5 |
JGC
J. Goldman & Co
New York
|
+$1.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$13.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.07M |
| 3 |
Goldman Sachs
New York
|
-$3.42M |
| 4 |
Morgan Stanley
New York
|
-$2.07M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$1.99M |
RIGL Hedge Fund Activity: Q2 2020 in Review
135 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q2 2020, worth a combined $265M — up 13% from $234M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new RIGL positions and 8 closed out — a net gain of 10 holders — while 52 added to existing stakes and 33 trimmed.
The largest buyer was BlackRock, adding an estimated $4.2M. The largest seller was Millennium Management, cutting an estimated $13.7M.
- 135 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q2 2020, up from 126 in Q1 2020.
- Funds reported $265M of Rigel Pharmaceuticals stock for Q2 2020, up 13% quarter-over-quarter.
- 18 funds opened new Rigel Pharmaceuticals positions in Q2 2020 and 8 closed out, a net change of +10 holders.
- The largest Rigel Pharmaceuticals buyer in Q2 2020 was BlackRock, an estimated $4.2M added.
- The largest Rigel Pharmaceuticals seller in Q2 2020 was Millennium Management, an estimated $13.7M sold.
Based on aggregated 13F filings for Q2 2020.